Neurotechnology News
-
Synaptive Medical Welcomes Chris Marrus as New Chief Commercial Officer
Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, is proud to announce the appointment of Chris Marrus as Chief Commercial Officer. This appointment underscores Synaptive’s commitment to driving sales, expanding its market presence, and advancing innovative solutions in imaging and surgical technology focused on combining the ...
-
Synaptive Medical Announces Timothy J. Scannell as New Chair of Board of Directors
Synaptive Medical, a global medical device and technology company solving surgical, imaging and data challenges, is pleased to announce the appointment of Timothy J. Scannell as the new Chair of the Board of Directors, effective June 20, 2023. Mr. Scannell joined Synaptive Medical’s Board of Directors in August 2022, bringing a wealth of experience and expertise in the medical device ...
-
EMOTIV Enlists Two Machine Learning Heavyweights as AI Takes Aim at the Human Brain
EMOTIV, the bioinformatics pioneer advancing understanding of the human brain using electroencephalography (EEG), today added two renowned scientists to its executive leadership team, naming Dr. Gary William Flake as Chief Technology Officer (CTO) and Dr. Scott Rickard as Chief AI Scientist. The new hires underscore EMOTIV’s strategic objectives to meet the quickening pace of advancements ...
By Emotiv Inc.
-
Neurolief Announces First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Major Depressive Disorder
Neurolief Ltd., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion® DP for the treatment of major depressive disorder (MDD). The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. The trial, MOOD, will assess the ...
-
New Data Demonstrates Substantial Reduction of Migraine Days Using Neurolief’s Digital Therapeutics Technology
Neurolief, a neurotechnology innovator, today announced new data released at the 64th Annual Scientific Meeting hosted by the American Headache Society (June 9-12th, 2022, Denver, CO). The real-world, open-label analysis presents clinically meaningful data on the prevention of migraine, including responder rate, reduction in monthly migraine days and reduction in medication use for those with ...
-
Neurolief’s Digital Therapeutics Neuromodulation System May Challenge Medication Therapies for the Treatment of Migraine
Neurolief, a neurotechnology innovator, today announces the publication of the SP301 study in the Pain and Therapy Journal that demonstrates the safety and efficacy of Relivion MG, Neurolief’s CE-marked and FDA cleared wearable neuromodulation system for at-home treatment of migraine with remote physician monitoring. The study is the first to prove that external concurrent stimulation of ...
-
Neuros Medical Announces Completion of QUEST Pivotal Trial 90-day Primary Endpoints
Neuros Medical, Inc., a medical device company developing an innovative, on-demand bioelectric nerve block therapy for patients with intractable post-amputation pain, announced today the completion of its QUEST Pivotal Trial 90-day primary endpoints. QUEST outcomes will remain blinded through the 12-month follow-up period, per protocol. QUEST is a 180-subject randomized, double blinded, active ...
-
Sense Neuro Diagnostics Participates in Mayo Clinic and ASU MedTech Accelerator
CINCINNATI, OH – March 30, 2022 – Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, has been selected to participate in the Mayo Clinic and Arizona State University MedTech Accelerator. The flagship program of the Mayo Clinic and ASU Alliance for Health Care was designed to provide early-stage medical device and ...
-
Synchron Expands Advisory Board as Brain-Computer Interface Device Stentrode Advances into Patients in US Clinical Trials
Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth. The members of the advisory board are visionaries across the technology, neuroscience and medical device industry, which include Edward ...
-
BrainScope Completes Large-Scale Clinical Studies of Concussion in Universities, High Schools and Concussion Clinics
BrainScope®, a medical neuro-technology company focused on concussion and mild traumatic brain injury (mTBI) assessment, announced today that it had concluded both algorithm development and clinical validation studies in adolescent and young adult populations using its objective, EEG-based technology. The purpose of the studies was to create and validate an objective, personalized capability ...
-
NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it successfully completed initial pre-clinical long-term testing of recording capabilities on its platform thin film electrode technology. In test ...
-
Belfast Newsletter - Health tech company creates 22 new jobs
Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings. The company specialises in combining neuroscience and technology to tackle global health ...
-
BrainScope Completes Agreement with 18,000 Member Yankee Alliance
BrainScope today announced a new system-wide agreement with Yankee Alliance to make BrainScope’s innovative point-of-care neuro-technology system available to the 18,000 members, including over 5000 outpatient facilities and senior centers, in Yankee Alliance. BrainScope is the only FDA cleared medical device that aids in the objective triage of head injured patients for suspected mild ...
-
BrainScope and Aon Secure IP-based Deal Funding Full Expansion of Commercial Activities and Pursuit of New Indications for BrainScope’s Next-Gen Medical Device Platform
Brain-assessment device innovator BrainScope, and Aon plc (NYSE: AON), a leading global professional services firm, today announced the completion of an intellectual property-based funding arrangement. The funding arrangement provides BrainScope with up to $35 million in capital to fund the full expansion of its commercial activities as well as to develop new clinical applications on its ...
-
Sense receives clearance to expand ongoing clinical trial to evaluate non-invasive brain scanner to sites in India and Canada
Clinical trial underway at five US hospital sites to evaluate Sense’s novel, non-invasive brain scanner to monitor intracranial hemorrhage in acute hospital setting Drug Controller General of India (DCGI) and Health Canada grant permission to conduct clinical trial at multiple sites in India and Canada Current standard of care lacks a means to monitor brain injury continuously, ...
-
Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain
Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced today the completion of enrollment in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study. QUEST is a 180-subject, randomized, double blinded, active sham controlled clinical trial that is being conducted ...
-
LOK Corporation and Sense Neuro Diagnostics Announce Commercial Partnership Focused on International Market
(August 17, 2021—Montreal, Canada and Cincinnati, Ohio) LOK Corporation, a manufacturing agent that helps companies develop and manage their international distribution network and Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients today announced a commercial partnership to bring innovative brain scanners being developed ...
-
NeuroNav Partners with Axial3D to improve neuronavigation using artificial intelligence
Axial3D is delighted to be working in partnership with NeuroNav to improve the neurosurgical navigation workflow using artificial intelligence (AI). Neurosurgery procedures are extremely complex requiring high precision to avoid damage to vital structures of the brain. Neuronavigation systems help to guide surgeons to perform an even more accurate surgery, decreasing the percentage of serious ...
By Axial3D
-
Neuros Medical Receives FDA Breakthrough Device Designation for its Novel Altius High Frequency Nerve Block System
Neuros Medical, Inc., announced today that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel High-Frequency Nerve Block system as an aid in the management of chronic intractable pain of the lower limb of adult amputees. The FDA Breakthrough Device Program is intended to help patients and health care providers receive timely ...
-
Fibralign Selected as a UCSF Rosenman Institute Innovator
The UCSF Rosenman Institute is proud to announce the 2021 cohort of the Rosenman Innovators, a group of early-stage health technology companies chosen for their innovative technologies and patient impact. 2021 is the sixth year for the Rosenman Innovator selection cycle, which has the goal of identifying promising companies seeking funding from seed stage to Series A. The number of companies ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you